With strong participation from existing investors including StartAngels and other business angels, the cantonal bank ZKB as well as from new investors, Peripal has now executed its adjacent Series A1 financing round to launch the products in the EU in and the US.
“We expect our Peripal System to facilitate the therapy process and to shorten training times. By making home dialysis easier and safer for patients, we also help to reduce healthcare costs”, says Sandra Neumann, founder and CEO of Peripal.
Peripal’s product addresses a key step in home dialysis: the manual connection of dialysis tubings to patients’ catheters. This handling by patients/relatives requires dexterity and car-ries the risk of infection, thereby posing a critical hurdle to home dialysis. Each day, more than 1 million such connections are performed worldwide.
“With the Series A1 financing, we will build up the production, further expand the team, and get ready for the EU launch in 2018. We are very excited to finally see the product in the market”, says Reto Koch, chairman of the board.
Chronic kidney failure increases at a rate of 2-4% annually, driven by age, diabetes, and hypertension. With the support of Peripal’s patient aid device, more patients can receive their therapy in a home setting as opposed to the hospital, resulting in considerable healthcare cost reductions and, hopefully, improved safety and quality of life.